A detailed history of Los Angeles Capital Management LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 103,005 shares of STOK stock, worth $1.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
103,005
Previous 66,765 54.28%
Holding current value
$1.43 Million
Previous $901,000 40.4%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$12.24 - $15.92 $443,577 - $576,940
36,240 Added 54.28%
103,005 $1.27 Million
Q2 2024

Aug 05, 2024

BUY
$11.03 - $17.52 $49,723 - $78,980
4,508 Added 7.24%
66,765 $901,000
Q4 2023

Feb 06, 2024

BUY
$3.37 - $5.4 $48,898 - $78,354
14,510 Added 30.39%
62,257 $327,000
Q3 2023

Nov 06, 2023

SELL
$3.78 - $11.99 $5,027 - $15,946
-1,330 Reduced 2.71%
47,747 $188,000
Q2 2023

Aug 03, 2023

BUY
$7.93 - $13.82 $79,474 - $138,504
10,022 Added 25.66%
49,077 $521,000
Q1 2023

May 04, 2023

SELL
$7.65 - $10.38 $10,388 - $14,096
-1,358 Reduced 3.36%
39,055 $325,000
Q4 2022

Feb 06, 2023

BUY
$7.07 - $15.69 $86,183 - $191,261
12,190 Added 43.19%
40,413 $373,000
Q2 2022

Aug 05, 2022

BUY
$10.36 - $23.93 $53,975 - $124,675
5,210 Added 22.64%
28,223 $373,000
Q1 2022

May 06, 2022

BUY
$17.19 - $26.1 $75,807 - $115,101
4,410 Added 23.71%
23,013 $484,000
Q4 2021

Feb 03, 2022

SELL
$18.11 - $30.72 $26,875 - $45,588
-1,484 Reduced 7.39%
18,603 $446,000
Q3 2021

Nov 08, 2021

BUY
$23.65 - $34.44 $70,240 - $102,286
2,970 Added 17.35%
20,087 $511,000
Q2 2021

Aug 05, 2021

BUY
$30.53 - $41.09 $522,582 - $703,337
17,117 New
17,117 $576,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $549M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.